Antibacterial Agents TRIZ Cases

Polyspecific binding sites enable a single antibody to neutralize multiple toxin families, replacing complex cocktails with one agent for broad coverage.

Mutant Listeria bacteria modulate interferon-beta production to resolve stability issues caused by aggregation and deamidation.

Deuterated pyridinone derivatives stabilize plasma concentrations via kinetic isotope effects, reducing hepatotoxicity and enabling less frequent dosing.

Aminoalcohol lipidoids buffer endosomal pH via proton-sponge effects, triggering vesicle rupture and payload release while avoiding cytotoxicity.

Yeast-based immunotherapeutic compositions deliver fusion proteins to induce robust Th1 and Th17 immune responses, countering waning vaccine efficacy in adults.

RNase degrades free ribosomal RNA to eliminate background noise, accelerating antimicrobial susceptibility testing and improving measurement precision.

Formula I compounds activate vitamin D receptors to treat endothelial dysfunction and proteinuria without causing hypercalcemia.

Peptides self-assemble into a hydrogel network holding metal nanoparticles to provide sustained antimicrobial activity without adhesive trauma.

Chimeric antimicrobial peptides bind bacterial ribosomes to inhibit protein synthesis, overcoming resistance through dual immunomodulatory mechanisms.

Cold-pressed Nigella sativa seed oil with optimized thymoquinone and free fatty acid levels inhibits fungal and bacterial growth.

Heterocyclic compounds inhibit the LpxC enzyme to block lipid A biosynthesis, addressing inadequate lung concentrations and resistant strains.

Plant extracts mediate between skin and environmental stressors while the enzyme repairs UV-induced damage, reducing irritation from conventional exfoliants.

Truncated mutant polypeptides retain translocating activity while suppressing pore-forming cytotoxicity.

Azatricyclic compounds with nitrogen-containing rings treat Gram-negative and Gram-positive bacteria without toxicological effects.

Modifying aza-bicycloalkyl structures enhances therapeutic effectiveness for psychotic and neurodegenerative disorders.

Replacing oxytetracycline with ovotransferrin eliminates antibiotic residues in milk while effectively treating metritis and maintaining fertility.

Catechol-modified mussel adhesive proteins coordinate with metal ions to form stable antimicrobial nanoparticles.

Novel monobactam antibiotic combines with carbapenems to overcome Gram-negative resistance.

Phenyl-heteroaryl compounds inhibit receptor for advanced glycation endproducts ligand binding to treat Alzheimer's disease and inflammation.

Composite poloxamer and xanthan gum formulation resolves controlled drug release and adhesion limitations of pure poloxamer matrices.

Synthesizing para-bromo domiphen bromide derivatives via segmented intermediates to deliver potent antimicrobial activity against bacteria and yeasts.

Apotransferrin reduces biofilm formation and bacterial invasion by 30-50% to overcome antibiotic resistance in chronic infections.

Selective 1,3-thiazol-2-yl benzamides minimize taste disturbances by avoiding P2X2/3 blockade.

InvG protein immunizes poultry against Salmonella while biofunctionalized carbon filters detect pathogens in viscous liquids without pre-enrichment steps.

Physical irradiation inactivates whole-cell Pseudomonas aeruginosa vaccines, eliminating formaldehyde toxicity and enabling safe industrial-scale production.

Formulations with fragmentation agents enable spontaneous particle formation, eliminating high-energy dispersion needs and protecting sensitive active agents.

Pre-enrichment of TSCM cells combined with optimized IL-2, IL-7, and IL-15 culture conditions maintains phenotype during expansion for improved persistence.

Genetically modified hematopoietic stem cells express extracellular ligand binding domains to target unwanted cancer cells.

Formula 1 compounds target GPR109A to overcome drug resistance in Mycobacterium tuberculosis treatment.

Adenosine receptor signaling down-regulates P-glycoprotein efflux transporters, improving chemotherapeutic bioavailability across the blood-brain barrier.

Engineered Saccharomyces yeast synthesizes therapeutic polypeptides in the gut, eliminating cold-chain distribution and purification costs.

Replacing alpha-lysine with epsilon-lysine in peptide sequences reduces mammalian cytotoxicity while maintaining potent inhibition of resistant pathogens.

Multimerized pharmamer constructs direct antigens to specific antigen-presenting cells via targeting ligands.

Leaching copper ions into a biocompatible solution eliminates pathogens without side effects or resistance development.

Recombinant Salmonella paratyphi A strain with extended O-antigen chain length.

MMP-9 binding proteins inhibit enzymatic activity, reducing toxicity in disease treatment.

Selective MAO-B inhibitor compounds designed to minimize blood-brain barrier penetration.

Segmenting the molecule into optimized heterocyclic cores and substituents achieves selective IRAK4 inhibition without increasing development complexity.

Small molecule inhibitors bind BMP receptors to block SMAD1/5/8 phosphorylation, resolving specificity issues against TGF-beta ligands.

A pleuromulin lipoic acid ester compound with strong antibacterial activity against multi-drug resistant bacteria.

Aminoglycosides paired with cationic porphyrins overcome antibiotic resistance in deep tissue infections by disrupting biofilms without light activation.

EVs carrying IL-12 and ESAT6 antigens overcome weak immunity from free cytokines by boosting CD4 and CD8 T-cell responses.